News
Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company's transformation and growth in autoimmune disease CAMBRIDGE, Mass., July ...
Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.
In a report released yesterday, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Merck & Company, with a price target of $83.00. The company’s shares closed yesterday at $83.71.
US regulators approved Moderna Inc.’s COVID-19 vaccine for children, but for a narrower group than before, continuing Robert ...
Stock indexes closed higher on Wall Street, enough to nudge the S&P 500 and the Nasdaq composite to more records. The S&P 500 ...
The Dow Jones Industrial Average climbed on Thursday (July 10) as investors brushed aside concerns over new tariff ...
U.S. stock indexes are mixed as Wall Street sizes up a batch of corporate quarterly results. Delta Air Lines led a rally in airline stocks after releasing a solid outlook ...
Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...
4d
Barchart on MSNPfizer Earnings Preview: What to ExpectWith a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing ...
Pfizer has boldly stepped into the burgeoning cannabis light market, giving the industry a serious growth spurt. The Cannabis ...
"We're going to be announcing pharmaceuticals, chips and various couple of other things - you know, big ones," Trump told ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results